CA2906072C - Analgesic compositions comprising halogenated volatile compounds - Google Patents

Analgesic compositions comprising halogenated volatile compounds Download PDF

Info

Publication number
CA2906072C
CA2906072C CA2906072A CA2906072A CA2906072C CA 2906072 C CA2906072 C CA 2906072C CA 2906072 A CA2906072 A CA 2906072A CA 2906072 A CA2906072 A CA 2906072A CA 2906072 C CA2906072 C CA 2906072C
Authority
CA
Canada
Prior art keywords
composition
peg
acid
subject
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2906072A
Other languages
English (en)
French (fr)
Other versions
CA2906072A1 (en
Inventor
Danguole Spakevicius
Heather Giles
Terry Farmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VAPOGENIX Inc
Original Assignee
VAPOGENIX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VAPOGENIX Inc filed Critical VAPOGENIX Inc
Priority to CA3179312A priority Critical patent/CA3179312C/en
Publication of CA2906072A1 publication Critical patent/CA2906072A1/en
Application granted granted Critical
Publication of CA2906072C publication Critical patent/CA2906072C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/08Ethers or acetals acyclic, e.g. paraformaldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2906072A 2013-03-15 2014-03-14 Analgesic compositions comprising halogenated volatile compounds Active CA2906072C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3179312A CA3179312C (en) 2013-03-15 2014-03-14 ANALGESIC COMPOSITIONS COMPRISING HALOGENATED VOLATILE COMPOUNDS

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361792383P 2013-03-15 2013-03-15
US61/792,383 2013-03-15
US201361814485P 2013-04-22 2013-04-22
US61/814,485 2013-04-22
PCT/US2014/028169 WO2014143964A2 (en) 2013-03-15 2014-03-14 Novel analgesic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3179312A Division CA3179312C (en) 2013-03-15 2014-03-14 ANALGESIC COMPOSITIONS COMPRISING HALOGENATED VOLATILE COMPOUNDS

Publications (2)

Publication Number Publication Date
CA2906072A1 CA2906072A1 (en) 2014-09-18
CA2906072C true CA2906072C (en) 2023-01-10

Family

ID=51538291

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2906072A Active CA2906072C (en) 2013-03-15 2014-03-14 Analgesic compositions comprising halogenated volatile compounds
CA3179312A Active CA3179312C (en) 2013-03-15 2014-03-14 ANALGESIC COMPOSITIONS COMPRISING HALOGENATED VOLATILE COMPOUNDS

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3179312A Active CA3179312C (en) 2013-03-15 2014-03-14 ANALGESIC COMPOSITIONS COMPRISING HALOGENATED VOLATILE COMPOUNDS

Country Status (10)

Country Link
US (5) US9655867B2 (https=)
EP (2) EP2968214B1 (https=)
JP (4) JP6669645B2 (https=)
CN (3) CN113712911A (https=)
AU (4) AU2014227996B2 (https=)
CA (2) CA2906072C (https=)
DK (1) DK2968214T3 (https=)
ES (1) ES2873964T3 (https=)
PL (1) PL2968214T3 (https=)
WO (1) WO2014143964A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2968214T3 (pl) * 2013-03-15 2021-11-02 Newvapogen, Inc. Nowe kompozycje przeciwbólowe
CA2955229C (en) * 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3325062A4 (en) 2015-07-20 2019-03-13 Medical Developments International Limited INHALER FOR INHALABLE LIQUIDS
WO2017011867A1 (en) 2015-07-20 2017-01-26 Medical Developments International Limited Inhaler device for inhalable liquids
WO2017011865A1 (en) 2015-07-20 2017-01-26 Medical Developments International Limited Inhaler device for inhalable liquids
US9554998B1 (en) 2015-08-04 2017-01-31 Damaso Fernandez Gines Composition of analgesic bioadhesive healing microspheres
CA3019582A1 (en) 2016-03-31 2017-10-05 Smartech Topical, Inc. Delivery system
AU2017325107B2 (en) 2016-09-06 2022-10-06 Medical Developments International Limited Inhaler device for inhalable liquids
GB201706969D0 (en) * 2017-05-02 2017-06-14 Medherant Ltd Formulation
CN107693560A (zh) * 2017-09-13 2018-02-16 冯威 一种具有镇痛功能的药学组合物
US11446237B2 (en) * 2019-03-08 2022-09-20 Taro Pharmaceutical Industries Ltd. Stable topical compositions of fenoldopam
CN110090197A (zh) * 2019-04-19 2019-08-06 广州芮一生物科技有限公司 一种可成膜的麻醉面膜膏
US20220347132A1 (en) * 2019-09-19 2022-11-03 Celista Pharmaceuticals Llc Sprayable liquid lidocaine solution
JP7515582B2 (ja) * 2019-11-06 2024-07-12 スマーテック トピカル,インコーポレイテッド シクロオキシゲナーゼ阻害剤の局所配合剤およびその使用
WO2021134029A1 (en) * 2019-12-24 2021-07-01 Ampersand Biopharmaceuticals, Inc. Topical nicotine for smoking cessation
EP4103151A1 (en) * 2020-02-11 2022-12-21 Taro Pharmaceutical Industries Ltd. Compositions comprising desoximetasone and tazarotene
EP4333826A4 (en) * 2021-05-05 2025-03-12 Smartech Topical, Inc. TOPICAL NAPROXEN FORMULATIONS AND THEIR USES
CN113289172B (zh) * 2021-05-31 2023-11-03 成都中医药大学附属医院 用于治疗急诊创伤性疼痛的芳香化甲氧氟烷吸入装置
EP4522112A1 (en) 2022-05-13 2025-03-19 Laboratorios Gebro Pharma, S.A. Pharmaceutical composition for topical administration comprising a volatile anaesthetic

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3216897A (en) * 1961-11-02 1965-11-09 Air Reduction Injectable anesthetic
AR206458A1 (es) 1975-03-17 1976-07-23 Minnesota Mining & Mfg Materiales de hoja termograficas y fototermograficas
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
JPS62281814A (ja) * 1986-05-27 1987-12-07 Teisan Seiyaku Kk 徐放化貼付剤
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5114715A (en) 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
US5114714A (en) 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
US5120561A (en) 1991-04-25 1992-06-09 American Lecithin Company Food composition and method
US5283372A (en) 1991-12-04 1994-02-01 Anaquest, Inc. Preparation of purified optical isomers of desflurane
US6007838A (en) 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
CA2500310C (en) 2002-10-11 2013-03-12 Baxter International, Inc. Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
ATE365034T1 (de) 2003-09-10 2007-07-15 Cristalia Prod Quimicos Farm Stabile pharmazeutische zusammensetzung einer fluorether-verbindung für die anästhesie, verfahren zur stabilisierung einer fluorether- verbindung, verwendung eines stabilisierungsmittels zum ausschluss des abbaus einer fluorether-verbindung
US20050079147A1 (en) 2003-10-14 2005-04-14 Bernard Delaey Wound healing compositions and uses
CA2663857C (en) * 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
CN101522180A (zh) * 2006-09-20 2009-09-02 得克萨斯大学体系董事会 用于区域麻醉和/和疼痛缓解的递送挥发性麻醉剂的方法
JP2008288365A (ja) * 2007-05-17 2008-11-27 Mitsubishi Electric Corp 半導体装置
EP2244783B1 (en) * 2008-01-22 2019-12-18 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
PL2244737T3 (pl) * 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
US7736537B1 (en) * 2008-01-24 2010-06-15 Mainstream Engineering Corp. Replacement solvents having improved properties for refrigeration flushes
WO2009117489A1 (en) 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
US8193232B2 (en) * 2009-02-13 2012-06-05 Topica Pharmaceuticals, Inc. Anti-fungal formulation
WO2010112974A2 (en) * 2009-03-31 2010-10-07 Freescale Semiconductor, Inc. System for tree sequence testing of a device and method for tree sequence testing of a device in a test framework architecture
CN109394689A (zh) * 2009-05-05 2019-03-01 德州大学系统董事会 挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
US8498853B2 (en) * 2009-07-20 2013-07-30 Exxonmobil Upstream Research Company Petrophysical method for predicting plastic mechanical properties in rock formations
CN101791291B (zh) * 2010-04-02 2011-12-28 徐州医学院 七氟醚静脉微乳剂及其制备方法
EP2723325A4 (en) * 2011-06-24 2015-03-11 Vapogenix Inc NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
RU2013155713A (ru) * 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
WO2013016511A1 (en) * 2011-07-27 2013-01-31 University Of Miami Stable liquid formulations of volatile gas anesthetics
PL2968214T3 (pl) * 2013-03-15 2021-11-02 Newvapogen, Inc. Nowe kompozycje przeciwbólowe

Also Published As

Publication number Publication date
US10507189B2 (en) 2019-12-17
JP6669645B2 (ja) 2020-03-18
AU2014227996A1 (en) 2015-10-08
AU2020220122A1 (en) 2020-09-03
EP3854389A1 (en) 2021-07-28
PL2968214T3 (pl) 2021-11-02
US20210077423A1 (en) 2021-03-18
CN105611921A (zh) 2016-05-25
JP2020037574A (ja) 2020-03-12
AU2018264078B2 (en) 2020-05-28
EP2968214A2 (en) 2016-01-20
WO2014143964A3 (en) 2014-11-20
JP2022031534A (ja) 2022-02-18
ES2873964T3 (es) 2021-11-04
US20160022603A1 (en) 2016-01-28
US20180250242A1 (en) 2018-09-06
CA3179312C (en) 2025-07-08
AU2018264078A1 (en) 2018-12-06
JP2016513727A (ja) 2016-05-16
US10071065B2 (en) 2018-09-11
EP2968214B1 (en) 2021-03-10
US11304913B2 (en) 2022-04-19
EP2968214A4 (en) 2017-04-12
AU2022204105A1 (en) 2022-06-30
US10688062B2 (en) 2020-06-23
US20170231924A1 (en) 2017-08-17
JP7410114B2 (ja) 2024-01-09
CA3179312A1 (en) 2014-09-18
WO2014143964A2 (en) 2014-09-18
JP2024026453A (ja) 2024-02-28
CN112933036A (zh) 2021-06-11
CA2906072A1 (en) 2014-09-18
US20200022928A1 (en) 2020-01-23
US9655867B2 (en) 2017-05-23
CN113712911A (zh) 2021-11-30
AU2014227996B2 (en) 2018-08-23
DK2968214T3 (da) 2021-06-07

Similar Documents

Publication Publication Date Title
US11304913B2 (en) Analgesic compositions
CA2760775C (en) Novel formulations of volatile anesthetics and methods of use for reducing inflammation
CN103764128A (zh) 用于治疗皮肤病症或疾病的新型制剂和方法
US20220378719A1 (en) Analgesic compositions comprising halogenated volatile compounds
AU2017203066B2 (en) Volatile anesthetic compositions and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190306

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250304

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250304

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250304

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202